Ekso Bionics (EKSO): Yesterday's Science Fiction is Today's Reality

Edward Kim  |

Our colleague Stephen L. Kanaval first discussed Ekso Bionics (EKSO) over six months ago, and we continue to be impressed with the progress this company is making as a pioneer in the field of exoskeleton robotics. We found this brief video, posted two months ago, to be particularly enlightening. It highlights the use of the company's Ekso GT exoskelelton at Alta Bates Summit Medical Center, the largest private, not-for-profit medical center in the East Bay area of northern California.


Source: Ekso Bionics YouTube Channel

Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. The company is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of research and development projects intended to benefit U.S. defense capabilities.

Ekso Bionics reported very good numbers for Q4 and full year 2016 last month, highlighting several corporate milestones:


Source: Ekso Bionics YouTube Channel

Since the company reported earnings in March, additional accomplishments include:


So, corporate milestones are being achieved, and the company is making a difference in medical and industrial settings. The stock chart, however, isn't one to be envied. The market has chewed on all of the progress the company has made and has cut the stock by more than half over the past year, down to a market cap of just $64 million. There's clearly a disconnect between the progress the company is making and the market's appreciation of that progress.

The market has also punished the stock severely on two notable recent occasions. In August 2016, in conjunction with its uplisting from OTC to NASDAQ, the company priced a steeply discounted offering of common stock at $4.00 - off of the last OTC sale at $6.24. Beyond the market quickly deciding that $6.24 was clearly the wrong price when $4.00 stock was sloshing around on the first day of NASDAQ trading, the stock offering also triggered a reset on the conversion price of the Series A preferred and the exercise price of certain warrants - as those holders had anti-dilution protection, which of course meant dilution for everyone else.

Then, in October 2016, after recovering most of what it had lost in August, the stock lost nearly 40% over two trading sessions on nearly 1.8 million shares of volume. Average daily volume in EKSO is about 110,000 shares. We're not privy to what exactly happened there, but would it surprise anyone if EKSO was victim to a pump and dump?

We're left to conclude that the company needs to do a better job of articulating the investment thesis to the right investor audience. This will help spread the message, get stock in the hands of more fundamentally oriented investors and keep the pump and dump scammers at bay. The ugly chart is masking a company that is changing lives for stroke and spinal cord injury patients and making industrial workers more productive and safer.

Please email us at content@equities.com if you are a Public Company and would like to see our Testimonials.

Trade Commission-FREE with Tradier Brokerage

Please click here if you would like information on our new trading platform.

Please click here if you're an investor and would like to see our weekly newsletter.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Market Movers

Sponsored Financial Content